Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are distinct autoimmune demyelinating conditions of the central nervous system. NMOSD is characterised by autoantibodies directed against the astrocytic water-channel protein aquaporin-4 (AQP4-IgG), leading to severe optic neuritis and longitudinally extensive transverse myelitis, often with relapsing attacks and residual disability. By contrast, MOGAD is defined by immunoglobulin G against myelin oligodendrocyte glycoprotein (MOG-IgG), with a broader phenotype encompassing optic neuritis, myelitis, acute disseminated encephalomyelitis-like presentations and cortical encephalitis. Although both disorders share overlapping MRI features, key radiological patterns—such as perineural optic nerve enhancement in MOGAD and central cord lesions in NMOSD—aid differential diagnosis. Recent advances have refined serological assays, revealed distinct cerebrospinal fluid profiles and informed consensus diagnostic criteria for each condition. Therapeutic strategies diverge: NMOSD management increasingly relies on targeted complement or interleukin-6 receptor blockade, whereas MOGAD responds robustly to high-dose corticosteroids and plasma exchange, with maintenance regimens under active investigation. Together, these insights underscore the necessity of precise antibody testing for prognosis, treatment selection and the design of future clinical trials.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease publication trend

The graph below shows the total number of articles in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease across all publications each year (not limited to Nature Index journals).

Technical terms

Neuromyelitis optica spectrum disorder (NMOSD): A relapsing inflammatory condition targeting optic nerves and spinal cord, usually associated with aquaporin-4 antibodies.

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): An inflammatory demyelinating syndrome defined by antibodies against MOG, with variable clinical presentations including optic neuritis and acute encephalomyelitis.

Aquaporin-4 IgG (AQP4-IgG): Autoantibody directed against the astrocytic water-channel protein AQP4, highly specific for NMOSD.

Myelin oligodendrocyte glycoprotein IgG (MOG-IgG): Autoantibody targeting myelin oligodendrocyte glycoprotein, central to MOGAD diagnosis and classification.

Optic neuritis: Inflammatory demyelination of the optic nerve leading to visual loss, pain on eye movement and characteristic MRI enhancement patterns.

Longitudinally extensive transverse myelitis (LETM): Spinal cord inflammation extending over three or more vertebral segments, typical of NMOSD.

Oligoclonal bands: Discrete IgG bands detected in cerebrospinal fluid, reflecting intrathecal antibody synthesis and aiding differentiation from multiple sclerosis.

References

1. Immunoglobulin A Antibodies Against Myelin Oligodendrocyte Glycoprotein in a Subgroup of Patients With Central Nervous System Demyelination. JAMA Neurology (2023).
2. Comparing clinical and imaging features of patients with MOG antibody-positivity and with and without oligoclonal bands. Frontiers in Immunology (2023).
3. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Frontiers in Neurology (2022).